Zimmer Biomet Holdings, Inc. ZBH Moat

Key data

The moat

Hospitals and surgeons pay Zimmer Biomet because the implant arrives with a trained representative in the room, a consigned tray of instruments, and a technique the surgeon has repeated for years. Leaving costs retraining, revision-risk exposure on a system the surgeon knows less well, and a fresh inventory build. That is a switching-cost moat, held at the individual surgeon level rather than the procurement contract, with a secondary cost and scale layer. Stryker's lock is the Mako robot and its 62% share of orthopedic robots on third-party estimate, Smith+Nephew holds roughly 11% of US knees, and J&J MedTech's orthopedic unit is being separated from its parent; none of them rests on the largest installed base of knee systems in the world.

What the moat produces is volume, not price. Knee revenue has risen for four straight years to $3.32 billion in 2025, and US knee share is put at 33% by a third-party estimate, ahead of Stryker at 29%. Price goes the other way: management reported an 80 basis point pricing headwind in the second quarter of 2026 against guidance of up to 100 basis points for the year, and said the headwinds have increased slightly over the last three quarters. Two quarters of disclosed price effect is thin, so treat that deterioration as provisional.

Widening or narrowing

The secondary layer, cost and scale, is genuinely improving. Revenue per employee went 386, 411, 452, 484 across 2022 to 2025 on a headcount that fell from 18,000 to 17,000, and operating margin held between 16.5% and 17.3% for three years after 10.0% in 2022. The ZimVie spine and dental separation completed March 1, 2022 breaks any revenue sequence crossing that date.

The profit pool has moved and the fat slice went elsewhere. Management said the lion's share of growth is Technology, the segment where Stryker installed 3,000 Mako systems by the end of 2025 against more than 2,000 a year earlier, with over two thirds of its US knees done robotically. The company holding the larger robot base is converting faster: Stryker knees grew 8.5% and hips 9.5% in 2025, against 4.7% and 4.5% here.

The honest case that the moat is thinner than the share number suggests is the return series. Vendor-basis return on invested capital ran 2.6%, 6.3%, 5.7%, 5.5% across 2022 to 2025, and never exceeded 6.3% in the ten years in the pack. Volume share is being held, economics are not improving with it. Narrowing.

What breaks it, and who

Robotics is the live break. Stryker's installed base doubled in two years and now anchors the surgeon relationship at the capital-equipment level rather than the tray level, which is a deeper lock than the one Zimmer Biomet holds. The ROSA platform appears in the filings for knees and hips, but no installed count sits in the pack, so the response remains asserted rather than proven.

Payment policy is the second. CMS has finalized a nationwide mandatory CJR-X bundled model for lower-extremity joint replacement, and the proposed CY2027 physician fee schedule carries a reduction of up to 20% for total joint procedures with a 7% specialty-level cut for orthopedic surgery. Management argues nobody who understands data will buy cheaper implants under bundles; the 80 basis point pricing drag is the counter-evidence.

The third is the US sales force conversion from independent agents to employees, where management said retention agreements are in place across the board, conceding that agents carry surgeon relationships out the door.

What would change the read in the next 12 to 18 months: a ROSA installed-base figure that closes the gap on Mako, the final CY2027 fee schedule, and whether DePuy Synthes under new ownership competes on price.

Closing thoughts

The moat is real but conditional and narrowing. Surgeon-level switching costs still hold a third of the US knee market and four straight years of knee revenue growth, yet they have never produced positive price, and the vendor return series has not cleared 6.3% in a decade. The checkable thing is the growth gap against Stryker in knees and hips, 4.7% against 8.5% and 4.5% against 9.5% in 2025, because that gap is the robot gap showing up in implant share. The moat strengthens if knee and hip growth converges with Stryker's while pricing drag stays inside 100 basis points, and weakens if the gap widens or the 2027 fee cuts push the drag past that range.